At the molecular level, 5-amino-1MQ functions as a competitive inhibitor of NNMT, demonstrating remarkable potency with an IC of 1.2 0.1 M under standard assay conditions (50 M SAM, 100 M nicotinic acid). This represents a dramatic 10-fold improvement over the parent compound 1-methylquinolinium, achieved through strategic amino group substitution that enhances binding affinity to the NNMT active site. The compound's mechanism centers on preventing the methylation of nicotinamide to 1-methylnicotinamide (1-MNA), thereby preserving nicotinamide for recycling back to NAD+ through the salvage pathway. This intervention effectively blocks what researchers have termed the "NNMT metabolic drain" a process that simultaneously depletes NAD+ precursors and consumes cellular methylation capacity
The post-resection data might therefore not be truly representative of the characteristics that would be observed under tumor-free conditions
Patients were classified into IGH and IGL groups according to the cutoff value of intracellular GSH levels
Studying humans is therefore urgently needed to determine the doseeffect relation of DR interventions in human cancer treatment
5 Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Peoples Republic of China
